166 related articles for article (PubMed ID: 37653435)
1. Retinoic acid and proteotoxic stress induce AML cell death overcoming stromal cell protection.
Liccardo F; Śniegocka M; Tito C; Iaiza A; Ottone T; Divona M; Travaglini S; Mattei M; Cicconi R; Miglietta S; Familiari G; Nottola SA; Petrozza V; Tamagnone L; Voso MT; Masciarelli S; Fazi F
J Exp Clin Cancer Res; 2023 Aug; 42(1):223. PubMed ID: 37653435
[TBL] [Abstract][Full Text] [Related]
2. Retinoic acid synergizes with the unfolded protein response and oxidative stress to induce cell death in FLT3-ITD+ AML.
Masciarelli S; Capuano E; Ottone T; Divona M; Lavorgna S; Liccardo F; Śniegocka M; Travaglini S; Noguera NI; Picardi A; Petrozza V; Fatica A; Tamagnone L; Voso MT; Lo Coco F; Fazi F
Blood Adv; 2019 Dec; 3(24):4155-4160. PubMed ID: 31834935
[TBL] [Abstract][Full Text] [Related]
3. Arsenic trioxide and all-trans-retinoic acid selectively exert synergistic cytotoxicity against FLT3-ITD AML cells via co-inhibition of FLT3 signaling pathways.
Wang LN; Tang YL; Zhang YC; Zhang ZH; Liu XJ; Ke ZY; Li Y; Tan HZ; Huang LB; Luo XQ
Leuk Lymphoma; 2017 Oct; 58(10):2426-2438. PubMed ID: 28276286
[TBL] [Abstract][Full Text] [Related]
4. LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML.
Beeharry N; Landrette S; Gayle S; Hernandez M; Grotzke JE; Young PR; Beckett P; Zhang X; Carter BZ; Andreeff M; Halene S; Xu T; Rothberg J; Lichenstein H
Blood Adv; 2019 Nov; 3(22):3661-3673. PubMed ID: 31751472
[TBL] [Abstract][Full Text] [Related]
5. All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo.
Ma HS; Greenblatt SM; Shirley CM; Duffield AS; Bruner JK; Li L; Nguyen B; Jung E; Aplan PD; Ghiaur G; Jones RJ; Small D
Blood; 2016 Jun; 127(23):2867-78. PubMed ID: 27103744
[TBL] [Abstract][Full Text] [Related]
6. Impact of CXCR4 inhibition on FLT3-ITD-positive human AML blasts.
Jacobi A; Thieme S; Lehmann R; Ugarte F; Malech HL; Koch S; Thiede C; Müller K; Bornhäuser M; Ryser M; Brenner S
Exp Hematol; 2010 Mar; 38(3):180-90. PubMed ID: 20035824
[TBL] [Abstract][Full Text] [Related]
7. Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells.
Larrue C; Saland E; Boutzen H; Vergez F; David M; Joffre C; Hospital MA; Tamburini J; Delabesse E; Manenti S; Sarry JE; Récher C
Blood; 2016 Feb; 127(7):882-92. PubMed ID: 26286850
[TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide and all-trans retinoic acid suppress the expression of FLT3-ITD.
Liang C; Peng CJ; Wang LN; Li Y; Zheng LM; Fan Z; Huang DP; Tang WY; Zhang XL; Huang LB; Tang YL; Luo XQ
Leuk Lymphoma; 2020 Nov; 61(11):2692-2699. PubMed ID: 32536235
[TBL] [Abstract][Full Text] [Related]
9. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
[TBL] [Abstract][Full Text] [Related]
10. Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia.
Park IK; Mundy-Bosse B; Whitman SP; Zhang X; Warner SL; Bearss DJ; Blum W; Marcucci G; Caligiuri MA
Leukemia; 2015 Dec; 29(12):2382-9. PubMed ID: 26172401
[TBL] [Abstract][Full Text] [Related]
11. Novel AXL-targeted agents overcome FLT3 inhibitor resistance in FLT3-ITD
Liu Y; Wei J; Liu J; Ma W; Duan Y; Liu D
Oncol Lett; 2021 May; 21(5):397. PubMed ID: 33777220
[TBL] [Abstract][Full Text] [Related]
12. PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD
He X; Zhu Y; Lin YC; Li M; Du J; Dong H; Sun J; Zhu L; Wang H; Ding Z; Zhang L; Zhang L; Zhao D; Wang Z; Wu H; Zhang H; Jiang W; Xu Y; Jin J; Shen Y; Perry J; Zhao X; Zhang B; Liu S; Xue SL; Shen B; Chen CW; Chen J; Khaled S; Kuo YH; Marcucci G; Luo Y; Li L
Blood; 2019 Aug; 134(6):548-560. PubMed ID: 31217189
[TBL] [Abstract][Full Text] [Related]
13. All-trans retinoic acid exerts selective anti-FLT3-ITD acute myeloid leukemia efficacy through downregulating Chk1 kinase.
Wang W; Jiang Z; Wang L; Wang A; Liu J; Chen C; Yu K; Zou F; Wang W; Liu J; Liu Q
Cancer Lett; 2020 Mar; 473():130-138. PubMed ID: 31904486
[TBL] [Abstract][Full Text] [Related]
14. LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia.
Yu Z; Du J; Hui H; Kan S; Huo T; Zhao K; Wu T; Guo Q; Lu N
Theranostics; 2021; 11(1):93-106. PubMed ID: 33391463
[No Abstract] [Full Text] [Related]
15. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase.
Yang X; Sexauer A; Levis M
Br J Haematol; 2014 Jan; 164(1):61-72. PubMed ID: 24116827
[TBL] [Abstract][Full Text] [Related]
17. 4-Hydroxyphenyl Retinamide Preferentially Targets FLT3 Mutated Acute Myeloid Leukemia via ROS Induction and NF-κB Inhibition.
Zhao XY; Zhang RR; Ye Q; Qiu F; Xu HY; Wei FG; Zhang H
Curr Med Sci; 2020 Oct; 40(5):810-816. PubMed ID: 33123895
[TBL] [Abstract][Full Text] [Related]
18. Stromal niche cells protect early leukemic FLT3-ITD+ progenitor cells against first-generation FLT3 tyrosine kinase inhibitors.
Parmar A; Marz S; Rushton S; Holzwarth C; Lind K; Kayser S; Döhner K; Peschel C; Oostendorp RA; Götze KS
Cancer Res; 2011 Jul; 71(13):4696-706. PubMed ID: 21546568
[TBL] [Abstract][Full Text] [Related]
19. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
Zhang W; Gao C; Konopleva M; Chen Y; Jacamo RO; Borthakur G; Cortes JE; Ravandi F; Ramachandran A; Andreeff M
Clin Cancer Res; 2014 May; 20(9):2363-74. PubMed ID: 24619500
[TBL] [Abstract][Full Text] [Related]
20. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
Long J; Jia MY; Fang WY; Chen XJ; Mu LL; Wang ZY; Shen Y; Xiang RF; Wang LN; Wang L; Jiang CH; Jiang JL; Zhang WJ; Sun YD; Chang L; Gao WH; Wang Y; Li JM; Hong DL; Liang AB; Hu J
Blood; 2020 Apr; 135(17):1472-1483. PubMed ID: 32315388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
